Midatech begins US clinical trial of MTX110 to treat DIPG
The study is a combined Phase I and II study in approximately 40 patients to be conducted at specialist centres at the University of California, San Francisco and
AscellaHealth has acquired CHAPPER healthcare, a specialty pharmaceutical wholesaler, distributor and services provider, for undisclosed amount.
The phase III pacific trial is a randomized, double-blinded, placebo-controlled, multi-center trial of Imfinzi in patients with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemotherapy concurrent with
Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn's disease, pediatric Crohn's disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis,